After exclusion of 3 (1.0%) patients with stage IV disease, the final analytic cohort included 309 BRCA1/2 and PALB2-positive women with operable breast cancer; 160 (51.8%) BRCA1, 130 (42.1%) BRCA2, and 19 (6.1%) PALB2 carriers. The gene discussed is BRCA2; the disease is breast carcinoma.